The tumour suppressor gene TP53 is often inactivated by loss of function mutations in CRC [9], although other genetic (APC and RAS) or epigenetic alterations (e.g. DNA methylation promoter silencing) may compromise TP53 response to DNA damage [10]. This evidence concerns the gene TP53 and colorectal carcinoma.